Eisai and Biogen present three‑year real‑world lecanemab data showing slower Alzheimer’s progression
Eisai and Biogen reported results from the LEADER real‑world study of lecanemab (LEQEMBI) in 560 early‑Alzheimer’s patients across 13 U.S. sites. Over a three‑year follow‑up, lecanemab reduced the risk of progression to moderate or severe dementia by 76% versus a matched natural‑history cohort and 81.1% of patients were stable or improved after an average of 18 months of treatment. The study also found 77% of patients with PET scans became amyloid‑negative and safety was consistent with prior trials.
Why it matters
The company says the data demonstrate sustained clinical benefit and a favorable safety profile, which could support continued market uptake and pricing of lecanemab. Analysts note that the real‑world evidence may strengthen revenue forecasts for both Eisai and Biogen.
Key facts
- 1The LEADER study included 560 patients across 13 U.S. clinical sites. prnewswire.com
- 2LEQEMBI patients had a 76% lower rate of progression to moderate or severe Alzheimer’s dementia compared with a matched natural‑history cohort (HR 0.24; 95% CI 0.15‑0.39). prnewswire.com
- 381.1% of patients were reported as stable (75.8%) or improved (5.3%) after an average of approximately 18 months of treatment. prnewswire.com
- 495.0% of patients were estimated to remain in the early stages of Alzheimer’s disease through three years of treatment. prnewswire.com
- 577% of patients with paired amyloid PET scans (33 of 43) became amyloid‑negative at a median follow‑up of 18.1 months. prnewswire.com
- 6ARIA‑E was observed in 6.6% of patients and ARIA‑H in 11.1%, consistent with prior studies. prnewswire.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.